Research interests of Prof. Dr. med. Dagmar Simon

1. Mechanisms of eosinophilic inflammation

Eosinophils play a role in host defence, in immunoregulation and remodelling. The precise functions of eosinophils in eosinophilic disorders have not been defined yet. We will investigate the functional roles of eosinophils in eosinophilic skin diseases with different underlying pathomechanisms.

Furthermore, we collaborate with researchers investigating the pathomechanisms of eosinophilic esophagitis, which has recently been described as a new entity and has been identified as atopic disease.

2. Atopic eczema

Atopic eczema is a chronic inflammatory skin disease characterized by an impaired skin barrier function as well as a type 2 biased immune response. The disease is triggered by environmental factots including allergens, microbes and irritants. We aim to further evaluate the inflammtory infiltrate, as well as the pathomechanisms resulting in recruitment and activation of inflammatory cells in the skin. Our next projects will focus on NKT cells, Th17 cells and the role of TSLP.

Selected publications Original papers

  1. Simon D, von Gunten S, Borelli S, Braathen LR, Simon HU. The Interleukin-13 production by peripheral blood T cells from atopic dermatitis patients does not require CD2 co-stimulation. Int Arch Allergy Immunol 2003;132:148-155.
  2. Simon HU, Ploetz S, Simon D, Seitzer U, Braathen LR, Menz G, Straumann A, Dummer R, Levi-Schaffer F. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells’ syndrome. Eur J Immunol 2003;33:834-839.
  3. Ploetz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J. Use of an anti-IL-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349:2332-2337.
  4. Baumann R, Casaulta C, Simon D, Conus S, Simon HU. Macrophage migratine inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway. FASEB 2003;17:2221-2230.
  5. Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen L, Simon HU. Reduced dermal infiltration of cytokine-expressing cells in atopic dermatitis following short-term topical tacrolimus treatment. J Allergy Clin Immunol 2004;114:887-895.
  6. Simon D, Marti H, Heer P, Simon HU, Braathen LR, Straumann A. Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases. J Allergy Clin Immunol 2005;115:1090-1092.
  7. Simon D, Vassina E, Yousefi S, Braathen LR, Simon HU. Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 2005;60:944-951.
  8. Vassina E, Leverkus M, Yousefi S, Braathen LR, Simon HU, Simon D. Increased expression and a potential antiinflammatory role of TRAIL in atopic dermatitis. J Invest Dermatol 2005;125:746-752. 
  9. Simon D, Lindberg RLP, Kozlowski E, Braathen LR, Simon HU. Epidermal caspase-3 cleavage associated with interferon-gamma expressing lymphocytes in acute atopic dermatitis lesions. Exp Dermatol 2006;15:441-446. 
  10. Simon D, Straumann A, Wenk A, Spichtin H, Braathen LR. Eosinophilic esophagitis: clinical relevance of wheat and rye sensitization and therapeutic efficacy of an elimination diet. Allergy 2006;61:1480-1483.
  11. Simon D, Braathen LR, Simon HU. Increased lipopolysaccharide-induced TNF-alpha, IFN-gamma, and IL-10 production in atopic dermatitis. Br J Dermatol 2007;157:583-586.
  12. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122-128.
  13. Simon D, Salemi S, Yousefi S, Simon HU. Primary resistance to imatinib in FIP1L1-PDGFRA positive leukaemia. J Allergy Clin Immunol 2008;121:1054-1056.
  14. Simon D, Wittwer J, Kostylina G, Büttiker U, Simon HU, Yawalkar N. Alefacept (LFA-3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008;122:423-424.


  1. Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy 2004;59:561-570. 
  2. Straumann A, Simon D, Simon HU. Eosinophilic esophagitis: New pathogenic insights. Curr Immunol Rev 2005;1:297-304. 
  3. Simon D, Braathen LR, Simon H-U. Anti-IL-5 therapy in eosinophilic diseases. Pathobiology 2005; 72:287-292.
  4. Simon D, Braathen LR, Simon HU. Anti-Interleukin-5-Therapie bei eosinophilen Erkrankungen. Hautarzt 2007; 58:122-127.
  5. Simon D, Simon HU. Eosinophilic diseases. J Allergy Clin Immunol 2007;119:1291-1300.